



CODEN [USA]: IAJPBB

ISSN : 2349-7750

INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

<http://doi.org/10.5281/zenodo.4127051>Available online at: <http://www.iajps.com>

Research Article

PATTERNS OF ANTIMICROBIAL RESISTANCE AMONG PATIENTS IN THE INTENSIVE CARE UNIT

Dr Zainab Tariq¹, Dr Mubashar Shaukat², Dr Shaista Khalid³¹ Shaikh Khalifa bin Zayed Al Nahyan Medical and Dental College, Lahore² Central Park Medical College, Lahore³ Mohi ud Din Islamic Medical College Mirpur AJ&K

Article Received: August 2020

Accepted: September 2020

Published: October 2020

Abstract:

Given the importance of nosocomial infections (HAI), it is essential to conduct follow-up studies to obtain the required data on local microorganisms and their susceptibility to antibiotics. This study investigated the pattern of antimicrobial resistance among patients in intensive care unit (ICU).

Study Design: A cross-sectional study.

Place and Duration: In the Medicine Unit-II of Jinnah Hospital Lahore for one-year duration from April 2019 to April 2020.

Methods: 100 samples were collected from patients admitted to the ICU with symptoms or symptoms of nosocomial infection. Blood, urine, tracheal aspirate, sputum, wound swab, pus, and tracheal tubes were sampled from each patient, cultured, and analyzed by antibiogram.

Results: The most common primary diagnosis was aspiration pneumonia (49%) and UTI (20%), respectively. The most common sites of infection were tracheal aspirates (54%). The most common sample-derived Gram-negative microorganisms were *Acinetobacter* spp (29%), *Klebsiella* spp (26%) and *Pseudomonas* spp (18%). *Klebsiella* spp., *Acinetobacter* spp. And *Pseudomonas* spp. They were the most common resistant organisms of all. *Klebsiella* spp were resistant to ceftriaxone (84.6%), ceftazidime (82.6%), amikacin (46.1%), gentamicin (66.6%) and quinolones (65-66.6%), respectively. *Acinetobacter* spp were resistant to ceftriaxone (85%), ceftazidime (88.8%), cefotaxime (85.7%), meropenem (79.3%), amikacin (86.2%), gentamicin (84.5%) and quinolones (86.2-89.2%). *Pseudomonas* spp were resistant to ceftriaxone (70.5%), ceftazidime (66.6%), amikacin (68.7%), gentamicin (58.8%), meropenem (52.9%) and quinolones (81.2-86.6%). Meropenem was the most sensitive antibiotic to *Klebsiella* spp (84.6%), and co-trimoxazole in *Acinetobacter* spp (60%), respectively. *Escherichia coli* were mostly isolated from urine, which was sensitive to amikacin (73.3%) and meropenem (86.6%), respectively.

Conclusion: Gram-negative pathogens obtained from ICU patients in our facilities show high resistance to antibiotics. Regular monitoring of resistance patterns of common pathogens in intensive care units is essential for the current application of sound antibiotic ceilings.

Key words: antibiotic, microbes, nosocomial infections, healthcare associated infections, antimicrobial resistance.

Corresponding author:

Dr. Zainab Tariq,

Shaikh Khalifa bin Zayed Al Nahyan Medical and Dental College, Lahore

QR code



Please cite this article in press Zainab Tariq et al, Patterns Of Antimicrobial Resistance Among Patients In The Intensive Care Unit., Indo Am. J. P. Sci, 2020; 07(10).

INTRODUCTION:

Infectious diseases are the main health problems in Pakistan, requiring frequent use of antimicrobials. Antibiotic-resistant bacteria are a major threat among critically ill patients. Infections in critically ill patients result in high rates of morbidity and mortality¹⁻². Due to significant disease processes and disturbed physiological condition, critically ill patients are more susceptible to various infections and the adverse effects of infection³⁻⁴. Many infectious diseases do not respond to conventional antimicrobials. Standard guidelines for treating a variety of microbes are not sufficient for this purpose. Healthcare-associated infections (HAIs) are especially important in intensive care units (ICUs), where the incidence is five times higher than that of the general inpatient population⁵⁻⁶. This is due to the increased use of invasive medical instruments such as mechanical ventilators, monitoring devices, blood and urine catheters, which in turn is a result of the overt use of broad-spectrum antibiotics. These patterns of antimicrobial resistance always change with time⁷. Due to the importance of HAI infections, it is extremely important to conduct follow-up studies to obtain the required data on local microorganisms and their susceptibility to antibiotics⁸⁻⁹. This study is designed to provide such information to our clinicians.

MATERIAL AND METHODS:

This cross-sectional study was held in the Medicine Unit-II of Jinnah Hospital Lahore for one-year duration from April 2019 to April 2020. 100 samples from patients with HAI infection criteria admitted to the intensive care unit. A structured case record form was completed for each patient. Clinical specimens included blood, urine, pus and secretions from the tracheal tube and swabs from postoperative wounds, collected and cultured in Eosin Methylene Blue (EMB), blood agar, chocolate agar, thioglycolate, and tryptic broth (TSB) and incubated at 37 ° C for 24 - 48 hours. The thioglycolate cultures and TSB flasks were re-incubated for at least 7 days and, if necessary, subcultures were grown on EMB agar plates with blood or chocolate agar. Blood, urine, tracheal aspirate, sputum, wound smear, pus, and tracheal tube samples were collected from each patient, cultured and analyzed by antibiogram. The study protocol was approved by the Institute's ethics committee, and each patient's family gave written informed consent prior to study entry. Data was analyzed using the Chicago Illinois version 16 Social Science Statistical Package (SPSS).

RESULTS:

Of the total of 100 samples obtained, 67% were male and 33% female. 30% of patients were aged 61-70 years, respectively, and 18% aged > 80 years.

Table-I*Frequency of different microorganisms from various samples (n=100).*

Microorganism	Blood	Urine	Tracheal Aspirate	Sputum	Wound Swab	Pus Endotracheal	Tube	Total (%)
<i>Acinetobacter spp</i>	3(10.3)	1 (3.4)	20 (68.9)	2 (6.8)	2 (6.8)	0	1 (3.4)	29(29)
<i>Klebsiella spp</i>	3 (11.5)	3(11.5)	16 (61.5)	2 (7.6)	0	2(7.6)	0	26(26)
<i>Pseudomonas spp</i>	1 (5.5)	4(22.2)	9 (50)	3 (16.6)	0	0	1 (5.5)	18(18)
<i>Escherichia coli</i>	2(13.3)	7(46.6)	4 (26.6)	0	1 (6.6)	1 (6.6)	0	15(15)
<i>Staphylococcus aureus</i>	0	0	5 (83.3)	1 (16)	0	0	0	6(6)
<i>Streptococcus</i>	0	4 (100)	0	0	0	0	0	4(4)
<i>Salmonella spp</i>	1 (100)	0	0	0	0	0	0	1(1)
<i>Morganella morganii</i>	0	1 (100)	0	0	0	0	0	1(1)
Total	10(10)	20(20)	54(54)	8(8)	3(3)	3(3)	2(2)	100(100)

The most common primary diagnoses were aspiration pneumonia (49%) and UTI (20%), respectively [Table 2].

Patterns of Antimicrobial Resistance Among Intensive Care Unit Patients

BJM Vol. 25 No. 2




Fig.-2 :Distribution of various microorganisms according to types of samples cultured.

Table-II
Primary diagnosis of these ICU patients. (n=100)

Primary Diagnosis	Frequency	Percentage
Aspiration Pneumonia	49	49.0
UTI	20	20.0
Septicaemia	11	11.0
Pneumonia	10	10.0
COPD with respiratory failure	4	4.0
Surgical wound infection	3	3.0
Empyema thoracic	3	3.0
Total	100	100.0

The most common sites of infection were tracheal aspirate (54%), urine (20%), blood (10%), and sputum (8%) [Table 1]. The most common sample-derived microorganisms were Acinetobacter spp (29%), Klebsiella spp (26%) and Pseudomonas spp (18%), Escherichia coli (15%), Staphylococcus aureus (6), Streptococcus (4%), Salmonella spp (1%) and Morganella morganii (1%) respectively [Table II]. Acinetobacter spp, Klebsiella spp, and Pseudomonas spp were most commonly detected in samples from tracheal aspirates. However, Escherichia coli was mostly isolated from urine samples.

Table-III

Distribution of microorganisms according to susceptibility to penicillin and cephalosporins groups of antibiotics. (n=100)

Microorganism	Amoxicillin		Piperacillin+		Ceftriaxone		Ceftazidime		Cefotaxime		
	Tazobactam (%)		Tazobactam (%)		Tazobactam (%)		Tazobactam (%)		Tazobactam (%)		
	S	R	S	R	S	R	S	R	S	R	
Acinetobacter spp	0(0)	1 (100)	2 (66.6) 1 (33.3) 4 (14.8)	1 (50) 4 (14.8)	23 (85.1)	3 (11.1)	24 (88.8)	2 (14.2)	12 (85.7)		
Klebsiella spp	0(0)	2 (100)	1 (33.3) 2 (66.6) 4 (15.3)	2 (66.6) 4 (15.3)	22 (84.6)	4 (17.3)	19 (82.6)	2 (28.5)	5 (71.4)		
Pseudomonas spp	0(0)	3 (100)	1 (50) 5 (29.4)	1 (50) 5 (29.4)	12 (70.5)	6 (33.3)	12 (66.6)	5 (45.4)	6 (54.5)		
Escherichia coli	-	-	2 (66.6) 3 (33.3) 3 (20)	1 (33.3) 3 (20)	12 (80)	5 (35.7)	9 (64.2)	1 (50)	1 (50)		
Staphylococcus aureus	-	-	2 (100) 0 (0) 0 (0)	0 (0) 0 (0)	4 (100)	0 (0)	5 (100)	-	-		
Streptococcus	1 (50)	1 (50)	- - 1 (25)	1 (25)	3 (75)	1 (25)	3 (75)	-	-		
Salmonella spp	-	-	- - 1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	-	-		
Morganella morganii	0(0)	1 (100)	- - 0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	0 (0)	1 (100)		
Total	1 (11.1) 8 (88.8) 38.4	8 (88.8) 18 (21.1)	8 (61.5) 5 (14.8)	5 (14.8) 19.5	77 (81)	20 (21.5)	73 (78.4)	10 (28.5) 25 (71.4)	25 (71.4) 10 (28.5)		

Table III, IV, V explains the sensitivity of various microorganisms to common antibiotics. *Klebsiella* spp., *Acinetobacter* spp. They were the most common resistant organisms of all. In Table 3, of the 95 samples, 77% of the samples were resistant to ceftriaxone and 73% to ceftazidime, respectively. They were mainly *Pseudomonas* spp., *Klebsiella* spp., *Acinetobacter* spp. *Klebsiella* spp. They were resistant to ceftriaxone (84.6%), ceftazidime (82.6%), amikacin (46.1%), gentamicin (66.6%), respectively. %) and quinolones (65-66.6%) [Table III, IV, V].

Table-IV											
		<i>Macrolides and lincosamides groups</i>									
<i>Distribution of microorganisms according to susceptibility to aminoglycosides</i>											
<i>of antibiotics. (n=100)</i>											
<i>Acinetobacter</i> spp	4(13.7)	25(86.2)	4(16.6)	20(84.4)	5(19.2)	21(80.7)	0	1(100)	1(50)	1(50)	
<i>Klebsiella</i> spp	14(53.8)	12(46.1)	8(33.3)	16(66.6)	8(40)	12(60)	0	2(100)	0	2(100)	
<i>Pseudomonas</i> spp	5 (31.2)	11(68.7)	7 (41.1)	10 (58.8)	8 (50)	8(50)	1(25)	3(75)	1(16.6)	5(84.4)	
<i>Escherichia coli</i>	11(73.3)	4(26.6)	7(50)	7(50)	8(57.1)	6(42.8)	-	-	-	-	
<i>Staphylococcus aureus</i>	1(20)	4(80)	1(16.6)	5(84.4)	0	4(100)	-	-	-	-	
<i>Streptococcus</i>	0	3(100)	1(25)	3(75)	0	3(100)	0	1(100)	0	1(100)	
<i>Salmonella</i> spp	-	-	1(100)	0	-	-	-	-	-	-	
<i>Morganella morganii</i>	0	1(100)	0	1(100)	0	1(100)	0	1(100)	0	1(100)	
Total	35(36.8)	60(63.1)	29(31.1)	64(68.8)	29(34.5)	55(65.4)	1(11.1)	8(88.8)	2(16.6)	10(84.4)	

Acinetobacter spp were resistant to ceftriaxone (85%), ceftazidime (88.8%), cefotaxime (85.7%), meropenem (79.3%), amikacin (86.2%), gentamicin (84.5%),) and quinolones (86.2-89.2%) [Table III, IV, V].

Table-V

Distribution of microorganisms according to susceptibility to quinolones and other groups of antibiotics. (n=100)

Microorganism	Ciprofloxacin (%)		Levofloxacin (%)		Meropenem (%)		Colistin (%)		Cotrimoxazole (%)	
	S	R	S	R	S	R	S	R	S	R
<i>Acinetobacter</i> spp	3(10.7)	25(89.2)	4(13.7)	25(86.2)	6(20.6)	23(79.3)	2(40)	3(60)	12(60)	8(40)
<i>Klebsiella</i> spp	8(33.3)	16(66.6)	8(34.7)	15(65.2)	22(84.6)	4(15.3)	2(66.6)	1(33.3)	2(18.8)	9(81.8)
<i>Pseudomonas</i> spp	2(13.3)	13(86.6)	3(18.7)	13(81.2)	8(47)	9(52.9)	1(20)	4(80)	0	8(100)
<i>Escherichia coli</i>	2(14.2)	12(85.7)	2(14.2)	12(85.7)	13(86.6)	2(13.3)	1(100)	0	2(33.3)	4(66.6)
<i>Staphylococcus aureus</i>	0	4(100)	1(25)	3(75)	3(50)	3(50)	0	2(100)	1(25)	3(75)
<i>Streptococcus</i>	0	3(100)	0	3(100)	1(25)	3(75)	1(50)	1(50)	0	2(100)
<i>Salmonella</i> spp	0	1(100)	0	1(100)	1(100)	0	-	-	-	-
<i>Morganella morganii</i>	0	1(100)	0	1(100)	0	1(100)	0	1(100)	0	1(100)
Total	15(16.6)	75(83.3)	18(19.7)	73(80.2)	54(54.5)	45(45.4)	7(36.8)	12(63.1)	17(32.6)	35(67.3)

Pseudomonas spp were resistant to ceftriaxone (70.5%), ceftazidime (66.6%), amikacin (68.7%), gentamicin (58.8%), meropenem (52.9%) and quinolones (81.2-86.6%) [Table III, IV, V]. Meropenem was the most sensitive antibiotic to *Klebsiella* spp. (84.6%), but *Acinetobacter* spp. They were still resistant to Meropenem and Amikacin, but susceptible to Cotrimoxazole (60%) [Table VI]. Table 4.5 showed that *Escherichia coli* were the most sensitive to amikacin (73.3%) and meropenem (86.6%), respectively. Gram-negative pathogens obtained from ICU patients in our facilities show high resistance to antibiotics.

DISCUSSION:

This study analyzes the epidemiology and microbiology of infections in ICU patients at tertiary care Hospital of Lahore city. Consistent with other studies, aspiration pneumonia (49%), pneumonia (10%), and UTI (20%) were the leading forms of infection in the subjects. The types of organisms that turned out to be the most problematic for ICU patients were *Acinetobacter* spp, *Klebsiella* spp, *Pseudomonas* spp, *Escherichia coli*¹⁰⁻¹¹. In our study, the most common sample-derived microorganisms were *Acinetobacter* spp (29%), *Klebsiella* spp (26%) and *Pseudomonas* spp (18%), *Escherichia coli* (15%) respectively, which is consistent with the results of other studies. In recent years, *Acinetobacter* spp. Have proven to be important pathogens in intensive care units, most of them resistant to ampicillin, carbenicillin, cefotaxime, chloramphenicol and gentamicin. In our study, *Acinetobacter* spp was the major cause of pneumonia based on tracheal aspirate samples and is resistant to ceftriaxone (85.1%), ceftazidime (88.8%), amikacin (86.2%), gentamicin (84, 4%) and fluoroquinolones (86.2-89.2%) respectively. This is in line with the results of a similar study conducted in India. Another type of antimicrobial resistant pathogen commonly found in ICU patients is *Klebsiella* spp, which produces extended spectrum beta-lactamases (ESBL). Our *Klebsiella* spp isolates showed high resistance to broad-spectrum cephalosporins and gentamicin (82.6-84.6% and 66.6%, respectively). But they were very sensitive to meropenem (84.6%). Gram-negative bacilli are often associated with nosocomial infections in intensive care units. Data from a multicenter observational study in the intensive care unit (ISS) in the United States have shown that *Pseudomonas* spp are often isolated from ICU specimens and exhibit particular resistance to fluoroquinolones. *Pseudomonas* spp¹². Isolates in this study accounted for 18%, mainly from tracheal and urine aspirates. In this study, *Pseudomonas* spp were resistant to ceftriaxone (70.5%), ceftazidime (66.6%), amikacin (68.7%), gentamicin (58.8%), meropenem (52.9%) and quinolones, respectively. (81.2-86.6%), which is strictly in line with other studies. In our study, *E. coli* was the most common pathogen obtained from patients with a urinary tract infection¹³⁻¹⁴. This is similar to the previous study. In this study, *Escherichia coli* species were fully susceptible to meropenem but resistant to ceftriaxone. In our study, similarly, *Escherichia coli* were mostly sensitive to meropenem (86.6%), amikacin (73.3%) and resistant to ceftriaxone (80%) and ceftazidime (64.2%), respectively. The multi-resistant species *Klebsiellae*, *Pseudomonas* and *Acinetobacter* added a new dimension to the problem of nosocomial infections¹⁵.

The panic situation is infection with *Acinetobacter* spp, where no single antibiotic has shown effective susceptibility.

CONCLUSION:

Antibiotics and similar drugs, collectively called antimicrobials, have been used for many years, since the First World War, to treat patients with infectious diseases. Since the 1940s, these drugs have significantly reduced the number of cases and deaths caused by infectious diseases. The use of antibiotics is beneficial when they are prescribed and taken properly. Their value in patient care is enormous. Infections caused by resistant microorganisms often fail to respond to conventional treatment, resulting in protracted illness, prolonged hospital stay, and a greater risk of death. A number of factors contribute to the emergence of antimicrobial resistance in intensive care units, including the severity of the patient's disease, predisposition to nosocomial infections, cross-transmission of pathogens characteristic of intensive care areas in a hospital, impairment of membrane and skin barriers after the use of invasive devices, extension in hospital and the widespread use of prophylactic and therapeutic anti-infective agents. Antimicrobial resistance among Intensive Care Unit (ICU) pathogens is gradually increasing but varies by country, possibly due to individual patterns of antimicrobial use. We need institutional surveillance mechanisms in the health sectors to generate reliable and practical epidemiological information, including basic data and trends on antimicrobial resistance, antimicrobial use, and economic and health impacts through designated national and regional centers of reference.

REFERENCES:

1. Nusrat, Tanzina, Nasima Akter, Nor Azlina A. Rahman, Brian Godman, Diana Thecla D. Rozario, and Mainul Haque. "Antibiotic resistance and sensitivity pattern of Metallo- β -Lactamase Producing Gram-Negative Bacilli in ventilator-associated pneumonia in the intensive care unit of a public medical school hospital in Pakistan." *Hospital practice* (2020): 1-9.
2. Ahmed, Iftexhar, Md Bodiuzzaman Rabbi, and Sakina Sultana. "Antibiotic resistance in Pakistan: A systematic review." *International Journal of Infectious Diseases* 80 (2019): 54-61.
3. Hoque, Roksana, Syed Masud Ahmed, Nahitun Naher, Mohammad Aminul Islam, Emily K. Rousham, Bushra Zarin Islam, and Shaikh Hassan. "Tackling antimicrobial resistance in Pakistan: A scoping review of policy and practice in human, animal and environment sectors." *PloS one* 15, no. 1 (2020): e0227947.

4. Rajopadhye, Bhagyashri D., Sonali H. Palkar, Vijaya A. Pandit, Priti P. Dhande, Mahadevan Kumar, and Sanjay K. Lalwani. "Antimicrobial prescribing pattern in a tertiary care teaching hospital: a pilot study." *International Journal of Basic & Clinical Pharmacology* 9, no. 3 (2020): 465.
5. Gebre-egziabher, Segen Tekle, Feleke Moges Yehuala, Zemene Tigabu Kebede, and Alem Getaneh Mehari. "Bacterial profile and their antibiotic resistance patterns from blood culture in Intensive Care Unit patients at the University Of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia." (2019).
6. Alemayehu, Tsegaye, Mulubrahan Ali, Enkosilassie Mitiku, and Mengistu Hailemariam. "The burden of antimicrobial resistance at tertiary care hospital, southern Ethiopia: a three years' retrospective study." *BMC infectious diseases* 19, no. 1 (2019): 585.
7. Iramiot, Jacob Stanley, Henry Kajumbula, Joel Bazira, Catherine Kansime, and Benon B. Asiiimwe. "Antimicrobial resistance at the human-animal interface in the Pastoralist Communities of Kasese District, South Western Uganda." *Scientific Reports* 10, no. 1 (2020): 1-15.
8. Saleem, Zikria, Hamid Saeed, Mohamed Azmi Hassali, Brian Godman, Usama Asif, Mahrukh Yousaf, Zakiuddin Ahmed, Humayun Riaz, and Syed Atif Raza. "Pattern of inappropriate antibiotic use among hospitalized patients in Pakistan: a longitudinal surveillance and implications." *Antimicrobial Resistance & Infection Control* 8, no. 1 (2019): 188.
9. Gandra, Sumanth, Gerardo Alvarez-Uria, Paul Turner, Jyoti Joshi, Direk Limmathurotsakul, and H. Rogier van Doorn. "Antimicrobial Resistance Surveillance in Low-and Middle-Income Countries: Progress and Challenges in Eight South Asian and Southeast Asian Countries." *Clinical Microbiology Reviews* 33, no. 3 (2020).
10. Ahmed, Fatima, Abubaker Koko, Ola Mohamed, Reem Elhag, Sufian Khalifa, Mohamed Mohamed, Hind Abdelaziz, Almegadad Ahmed, and Ihab Abdelrahman. "Antibiotics prescription pattern and resistance profile of common isolates at Soba university hospital in Khartoum, Sudan, a retrospective cross sectional study." (2020).
11. Iskandar, Katia, Massimo Sartelli, Marwan Tabbal, Luca Ansaloni, Gian Luca Baiocchi, Fausto Catena, Federico Coccolini et al. "Highlighting the gaps in quantifying the economic burden of surgical site infections associated with antimicrobial-resistant bacteria." *World Journal of Emergency Surgery* 14, no. 1 (2019): 50.
12. Tiroyakgosi, Celda, Matshediso Matome, Joyce Kgatlwane, Bene D. Anand Paramadhas, Brighid Malone, Pinkie Mpinda-Joseph, Godfrey Mutashambara Rwegerera et al. "Antimicrobial utilization research and activities in Botswana, the past, present and the future." *Expert review of anti-infective therapy* 17, no. 10 (2019): 759-762.
13. Mpinda-Joseph, Pinkie, Bene D. Anand Paramadhas, Gilberto Reyes, Mompoloki Buster Maruatona, Mamiki Chise, Baphaleng B. Monokwane-Thupiso, Sajini Souda, Celda Tiroyakgosi, and Brian Godman. "Healthcare-associated infections including neonatal bloodstream infections in a leading tertiary hospital in Botswana." *Hospital practice* 47, no. 4 (2019): 203-210.
14. Kalungia, Aubrey Chichonyi, Haabingozi Mwambula, Derick Munkombwe, Sarah Marshall, Natalie Schellack, Claire May, Anja St Claire Jones, and Brian Godman. "Antimicrobial stewardship knowledge and perception among physicians and pharmacists at leading tertiary teaching hospitals in Zambia: implications for future policy and practice." *Journal of chemotherapy* 31, no. 7-8 (2019): 378-387.
15. Myat, Tin Ohn, Khine Mar Oo, Hla Kye Mone, Wah Win Htike, Ambarish Biswas, Rachel F. Hannaway, David R. Murdoch, James E. Ussher, and John A. Crump. "A prospective study of bloodstream infections among febrile adolescents and adults attending Yangon General Hospital, Yangon, Myanmar." *PLoS neglected tropical diseases* 14, no. 4 (2020): e0008268.